EUCTR2014-005717-23-Outside-EU/EEAActive, not recruitingNot Applicable
A Long Term Immunogenicity, Safety, and Effectiveness Study of GARDASIL™ (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) Among Adolescents Who Received GARDASIL™ at 9-18 Years of Age - A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.0 sites1,575 target enrollmentStarted: December 18, 2015Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Enrollment
- 1,575
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Healthy adolescents and preadolescents (9 Years to 15 Years Old) with no prior sexual history
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 801
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 289
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Subjects with compromised immune system or have a history of severe allergic reaction
Investigators
Similar Trials
Active, not recruiting
Phase 1
A Long-Term Safety and Immunogenicity Follow-up of Healthy Adults Vaccinated with One Dose of Smallpox Vaccine (LISTER Strain).Five year follow-up of healthy adults already vaccinated in a previous trialEUCTR2006-000715-19-FRSanofi Pasteur SA230
Active, not recruiting
Not Applicable
Follow-up study to evaluate the long-term immunogenicity and safety ofGlaxoSmithKline Biologicals' HPV (580299) vaccine in healthy femalesubjects.EUCTR2009-011357-41-DEGlaxoSmithKline Biologicals667
Active, not recruiting
Not Applicable
A long-term, open, follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV 014. - HPV-060 EXT 014 Y5-10For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC US) and cervical intraepithelial neoplasia (CIN), CIN1 and pre-cancerous lesions (CIN2 and CIN3), caused by oncogenic human papillomavirus (HPV) types 16 and 18.EUCTR2009-011357-41-PLGlaxoSmithKline Biologicals667
Completed
Phase 3
Durability of Immunogenicity and Effectiveness of the heterologous COVID-19 vaccination in kidney transplant recipientsImmunogenicity of the vaccineEffectiveness of the vaccinehumoral immunity, cell-mediated immunity, SARS-CoV-2, immunization, immunocompromisedTCTR20220511002ational Council Researach of Thailand100
Active, not recruiting
Not Applicable
A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV-013. - HPV-025 EXT 013For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.EUCTR2008-000369-44-DEGlaxoSmithKline Biologicals600